In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 .

To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

Roger starts this conversation with a metaphor suggesting that as the FibroScan initiative takes shape, different stakeholders and communities might start out in different directions. Later, Louise suggests that the regions should rethink their funding to make it, as she puts it, bottom up instead of top down, and discusses other steps necessary to equalize delivery of quality scanning care throughout the US. Louise also mentions that the NHS recently announced investment in community scanning centers over the next two years in making all this work. The conversation winds down with Vanessa talking about work the British Liver Trust has done to assess different regions abilities to analyze and act on abnormal tests and more recently, conversations with integrated care boards on this topic. She goes on to discuss some of the challenges with producing change within NHS.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!